Advertisement

Digestive Diseases and Sciences

, Volume 50, Issue 3, pp 474–482 | Cite as

Biomarkers in Various Types of Atrophic Gastritis and Their Diagnostic Usefulness

  • Kazimierz Rembiasz
  • Peter C. Konturek
  • Danuta Karcz
  • Stanislaw J. KonturekEmail author
  • W↰ADYS↰AW Ochmanski
  • Wladyslaw Bielanski
  • Andrzej Budzynski
  • Jerzy Stachura
Article

Abstract

Atrophic gastritis has been shown to involve either the oxyntic gland area, resulting in hypergastrinemia and hypopepsinogenemia I, the antral gland area, causing hypogastrinemia without change in serum pepsinogen I (diffuse antral gastritis; DAG), or the entire gastric mucosa (multifocal atrophic gastritis; MAG), resulting in both hypogastrinemia and hypopepsinogenemia I; and rare atrophic gastritis limited to the oxyntic gland area, with antibodies against oxyntic cells and/or intrinsic factor (autoimmune metaplastic atrophic gastritis; AMAG). This study was performed on 126 patients with various forms of gastritis and on 126 age- and gender-matched controls, who were subjected to endoscopy with biopsy, H. pylori testing (13C-UBT, serology), assays for serum gastrin and pepsinogen I, and testing for basal and pentagastrin-induced gastric acid secretion. The following groups of patients were examined: group I (N = 22), with AMAG; group II (N = 53), with DAG; group III (N = 51), with MAG; and group IV (N = 126), age- and gender-matched controls without gastritis. The following changes were found. In group I very high serum gastrin and very low pepsinogen I were observed, and all patients were achlorhydric and H. pylori negative. In group II, with low serum gastrin and normal pepsinogenemia and gastric chlorhydria, all patients were H. pylori positive. In group III, with lower serum gastrin and lower pepsinogen I levels and reduced chlorhydria, all patients were also H. pylori positive. And all group IV controls, with normal serum gastrin and pepsinogen I and normal gastric acid secretion without antral or fundic gastritis, were H. pylori negative. We conclude that measurements of serum gastrin and pepsinogen I and gastric acid secretion as well as testing for H. pylori infection may be useful in noninvasive diagnosis of various types of atrophic gastritis and in identification of patients with premalignant gastritis and a high risk of gastric cancerogenesis.

Keywords:

atrophic gastritis gastrin pepsinogen I H. pylori antibodies against oxyntic cells 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Strickland RG, Mackay IR: A reappraisal of the nature and significance of chronic atrophic gastritis. Am J Dig Dis 18:426–440, 1973PubMedGoogle Scholar
  2. 2.
    Correa P: The epidemiology and pathogenesis of chronic gastritis: three etiologic entities. Front Gastrointest Res 6:98–108, 1980PubMedGoogle Scholar
  3. 3.
    Wyatt JI, Dixon MF: Chronic gastritis—A pathogenetic approach. J Pathol 154:113–124, 1988PubMedGoogle Scholar
  4. 4.
    Stolte M, Heilmann KL: Neue Klassifikation und Graduierung der Gastritis. Leber Magen Darm 19:220–226, 1989PubMedGoogle Scholar
  5. 5.
    Price AB: The Sydney system: Histological division. J Gastroenterol Hepatol 6:209–222, 1991PubMedGoogle Scholar
  6. 6.
    Sipponen P, Kekki M, Siurala M: The Sydney System: Epidemiology and natural history of chronic gastritis. J Gastroenterol Hepatol 6:244–251, 1991PubMedGoogle Scholar
  7. 7.
    Dixon MF, Genta RM, Yardley JH, Correa P, participants in the International Workshop on the Histopathology of Gastritis, Houston 1994: Classification and grading of gastritis. The updated Sydney system. Am J Surg Pathol 20:1161–1181, 1996Google Scholar
  8. 8.
    Correa P: Chronic gastritis: A clinico-pathological classification. Am J Gastroenterol 83:504–509, 1988.PubMedGoogle Scholar
  9. 9.
    Yardley JH, Hendrix TR: Gastritis, duodenitis and associated ulcerative lesions. In: Yamada T (ed) Textbook of Gastroenterology, Philadelphia, JB Lippincott, 1995Google Scholar
  10. 10.
    Craannen ME, Blok P, Dekker W, Ferwerda J, Tytgat GN: Subtypes of intestinal metaplasia and Helicobacter pylori. Gut 33:597–600, 1992Google Scholar
  11. 11.
    Genta RM: Recognizing atrophy: Another step toward a classification of gastritis. Am J Surg Pathol 20:S23–S30, 1996PubMedGoogle Scholar
  12. 12.
    Hughes SF, Winslet MC: Premalignant lesion of the stomach. Part I: Atrophic gastritis and gastric atrophy. Part II: Intestinal metaplasia. GI Cancer 3:157–180, 2000Google Scholar
  13. 13.
    Morson B, Dawson I: Gastritis In: Morson & Dawson’s Gastrointestinal Pathology. London, Blackwell Scientific, 1990Google Scholar
  14. 14.
    Mukawa K, Nakamura T, Nakano G, Nagamachi Y: Histopathogenesis of intestinal metaplasia: minute lesion of intestinal metaplasia in ulcerated stomach. J Clin Pathol 40:13–18, 1987PubMedGoogle Scholar
  15. 15.
    Peterson J, Borch K, Franzen LE: Prevalence of subtypes of intestinal metaplasia in the general population and in patients with autoimmune chronic atrophic gastritis. Scand J Gastroenterol 37:262–266, 2002Google Scholar
  16. 16.
    Rembiasz K, Urban A, Szczudrawa J, Bobrzynski A, Oszacki J: Wystepowanie i topografia metaplazji blony sluzowej zoladka u chorych na wrzod zoladka, wrzod dwunastnicy i w grupie kontrolnej. Pat Pol 35:287–308, 1984PubMedGoogle Scholar
  17. 17.
    Sipponen P, Seppala K, Varis K, Hjelt L, Ihamaki T, Kekki M, Siurala M: Intestinal metaplasia with colonic-type sulphomucins in the gastric mucosa; its association with gastric carcinoma. Acta Path Microbiol Scand 88:217–224, 1980Google Scholar
  18. 18.
    Correa P: Human gastric carcinogenesis: A multistep and multifactorial process—First American Cancer Society award lecture on cancer epidemiology and prevention. Cancer Res 52:6735–6740, 1992PubMedGoogle Scholar
  19. 19.
    Sipponen P, Kekki M, Haapakoski J, Ihamaki T, Siurala M: Gastric cancer risk in chronic atrophic gastritis. Statistical calculations of cross-sectional data. Int J Cancer 35:173–177, 1985PubMedGoogle Scholar
  20. 20.
    Sipponen P: Intestinal metaplasia and gastric carcinoma. Ann Clin Res 13:139–143, 1981PubMedGoogle Scholar
  21. 21.
    Tytgat GNJ: Review article: practical management issues for the Helicobacter pylori-infected patient at risk of gastric cancer. Aliment Pharmacol Ther 12:123–128, 1998PubMedGoogle Scholar
  22. 22.
    Bielanski W, Konturek SJ: New approach to 13C-urea breath test: capsule-based modification with low-dose of 13C-urea in the diagnosis of Helicobacter pylori infection. J Physiol Pharmacol 47:545–553, 1996PubMedGoogle Scholar
  23. 23.
    Kuipers EJ: Review article: Relationship between Helicobacter pylori, atrophic gastritis and gastric cancer. Aliment Pharmacol Ther 12:25–36, 1998PubMedGoogle Scholar
  24. 24.
    Peterson WL: Review article: Helicobacter pylori and gastric adenocarcinoma. Aliment Pharmacol Ther 16:40–46, 2002PubMedGoogle Scholar
  25. 25.
    Sipponen P, Hyvarinen H, Seppala K, Blaser MJ: Review article: pathogenesis of the transformation from gastritis to malignancy. Aliment Pharmacol Ther 12:61–71, 1998PubMedGoogle Scholar
  26. 26.
    Oksanen A, Sipponen P, Karttunen R, Miettinen A, Veijola L, Sarna S, Rautelin H: Atrophic gastritis and Helicobacter pylori infection in outpatients referred for gastroscopy. Gut 46(4):460–463, 2000PubMedGoogle Scholar
  27. 27.
    Oksanen A, Sipponen P, Miettinen A, Sarna S, Rautelin H: Evaluation of blood tests for predicting normal gastric mucosa. Gut 45 (3S):126–127, 1999Google Scholar
  28. 28.
    Sipponen P, Samloff IM, Saukkonen M, Varis K: Serum pepsinogens I and II and gastric mucosal histology after partial gastrectomy. Gut 26:1179–1182, 1985PubMedGoogle Scholar
  29. 29.
    Sipponen P, Linnala A, Sande N, Vaananen H, Rasmussen M, Tunturi-Hihnala H, Sotka M, Turunen M, Sandstrom R, Heiskanen I, Suovaniemi O, Harkonen M: Serum levels of gastrin-17 pepsinogen I and H. pylori antibodies in nonendoscopic diagnosis of atrophic gastritis. Gut 49:1718, 2001Google Scholar
  30. 30.
    Samloff IM, Varis K, Ihamaki T, Siurala M, Rotter JI: Relationships among serum pepsinogen I, pepsinogen II and gastric mucosal histology. A study in relatives of patients with pernicious anemia. Gastroenterology 83:204–209, 1982PubMedGoogle Scholar
  31. 31.
    Knight T, Wyatt J, Wilson A, Greaved S, Newell D, Hengels K, Corlett M, Webb P, Forman D, Elder J: H. pylori gastritis and serum pepsinogen levels in a healthy population: development of a biomarker strategy for gastric atrophy in a high risk group. Br J Cancer 73:819–824, 1996PubMedGoogle Scholar
  32. 32.
    Matsumoto K, Konishi N, Ohshima M, Hiasa Y, Kimura E, Samori T: Association between Helicobacter pylori infection and serum pepsinogen concentration in gastroduodenal diseases. J Clin Pathol 49:1005–1008, 1996PubMedGoogle Scholar
  33. 33.
    Plebani M, Basso D, Scrigner M, Toma A, Di Mario F, Dal Bo N, Samloff IM: Serum pepsinogen C a useful marker of H. pylori eradication? J Clin Lab Anal 10:1–6, 1996PubMedGoogle Scholar
  34. 34.
    Westerveld BD, Pals G, Lamers CB, Defize J, Pronk JC, Frants RR, Ooms EC, Kreuning J, Kostense PJ, Eriksson AW: Clinical significance of pepsinogen A isozymogens, serum pepsinogen A and C levels, and serum gastrin levels. Cancer 59:952–958, 1987PubMedGoogle Scholar
  35. 35.
    Sipponen P, Samloff IM, Saukkonen M, Varis K: Serum pepsinogen I and II and gastric mucosal histology after parietal gastrectomy. Gut 26:1179–1182, 1985PubMedGoogle Scholar
  36. 36.
    Kitahara F, Kobyashi K, Sato T, Kojima Y, Araki T, Fujimo MA: Accracy of screening of gastric cancer using serum pepsinogen concentrations. Gut 44:693–697, 1999.CrossRefPubMedGoogle Scholar
  37. 37.
    Konturek SJ, Konturek PC, Bielanski W, Lorens K, Sito E, Konturek JW, Kwiecien S, Bobrzynski A, Pawlik T, Karcz D, Areny H: Case presentation of gastrinoma combined wih carcinoidband with longest survival record—Zollinger–Ellison syndrome. Med Sci Monit 8:CS43–59, 2002PubMedGoogle Scholar
  38. 38.
    Konturek PC, Konturek SJ, Bielanski W, Kania J, Zuchowicy M, Harwich A, Rehfeld JF, Hahn EG: Influence of COX+2 inhibition bz rofecoxib on serum and tumor progastrin and gastrin levels and expression of PPARgamma and apoptosis related proteins in gastric cancer patients. Dig Dis Sci 48:2005–2017, 2003PubMedGoogle Scholar
  39. 39.
    Waldum HL, Fossmark, Bakke I, Martinsen TC, Qvigstad G: Hypergastrinemia in animals and man. Causes and consequences. Scand J Gastroenterol 39:505–509, 2004PubMedGoogle Scholar
  40. 40.
    Varis K, Kekki, N, Harkonen, Samloff IN: Serum pepsinogen and serum gastrin in screening of atrophic gastritis and high risk of gastric cancer. Scand J Gastroenterol 186:117–123, 1991Google Scholar
  41. 41.
    Bechi P, Bacci S, Cianchi F, Amarosi A, Nesi G, Dei R, Romagnoli P: Impairement of gastric secretion modulation in duodenal ulcer and in long-term PPI treatment. Quantitative morphologic findings and pathophysiologic implications. Dig Dis Sci 46:1952–1959, 2001PubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  • Kazimierz Rembiasz
    • 1
  • Peter C. Konturek
    • 1
  • Danuta Karcz
    • 1
  • Stanislaw J. Konturek
    • 1
    • 2
    Email author
  • W↰ADYS↰AW Ochmanski
    • 1
  • Wladyslaw Bielanski
    • 1
  • Andrzej Budzynski
    • 1
  • Jerzy Stachura
    • 1
  1. 1.Department of GastroenterologyAcademy of Medicine, Institute of PhysiologyKrakowPoland
  2. 2.Department of GastroenterologyAcademy of Medicine, Institute of PhysiologyKrakowPoland

Personalised recommendations